Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Glioblastoma Multiforme (GBM) Treatment Market Forecast Highlighting Growth From $3.01 Billion To $4.45 Billion
The market for glioblastoma multiforme (gbm) treatments has experienced significant expansion recently. Projections indicate a progression from $2.73 billion in 2025 to $3.02 billion in 2026, signifying a compound annual growth rate (CAGR) of 10.7%. During the preceding period, this growth was fueled by factors such as the limited survival rates associated with the condition, the established reliance on surgical and radiation interventions, consistent chemotherapy protocols, the proliferation of specialized neuro-oncology centers, and an uptick in brain tumor diagnoses.
The glioblastoma multiforme (gbm) treatment sector is poised for substantial expansion in the coming years, projecting a market valuation of $4.46 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.2%. This anticipated surge is fueled by several key factors, including advancements in targeted therapies, the broadening landscape of immunotherapy candidates, the increasing integration of precision medicine, heightened clinical trial initiatives, and augmented research investment. Significant developments expected during this projection period encompass the broader implementation of multifaceted treatment strategies, a greater reliance on tumor treating field therapy, a strengthening emphasis on customized gbm treatments, the diversification of immunotherapy methodologies, and the refinement of therapeutic approaches following surgical intervention.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp
Glioblastoma Multiforme (GBM) Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?
The escalating incidence of neurological conditions is anticipated to drive the expansion of the glioblastoma multiforme (GBM) treatment sector in the foreseeable future. Neurological conditions encompass the aberrant functioning of the brain, along with the nervous system throughout the human body and the spinal cord. Factors contributing to the rising occurrence of brain disorders like glioblastoma multiforme (GBM) include an aging demographic, weakened immune responses, heightened diagnostic detection, exposure to ionizing radiation, atmospheric contamination, and other elements, thus necessitating therapies for these brain disorders to enhance health outcomes. As an illustration, in February 2025, Dementia Australia, a charitable entity based in Australia, reported that an estimated 433,300 individuals in Australia are currently diagnosed with dementia, and this figure is projected to reach 812,500 by the year 2054. Furthermore, dementia manifesting at a younger age impacts approximately 29,000 people in 2025, with forecasts suggesting an increase to 41,000 by 2054. Consequently, the growing prevalence of brain disorders is a key factor fueling the growth of the glioblastoma multiforme (GBM) treatment market.
Glioblastoma Multiforme (GBM) Treatment Market Segmentation Trends And Revenue Drivers
The glioblastoma multiforme (gbm) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, R Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies
Glioblastoma Multiforme (GBM) Treatment Market Trends: What Is Shaping Future Industry Growth?
Key players in the current market landscape are concentrating their efforts on creating cutting-edge wearable and portable gadgets to solidify their standing. The goal of these technological strides is to furnish consumers with superior features, ease of use, and a comfortable experience, thereby addressing the increasing need for readily available and effective health management tools. As an illustration, in the year 2023, Novocure, a cancer-focused firm headquartered in Jersey, introduced Optune Gio, a wearable and transportable therapeutic apparatus for individuals diagnosed with fresh glioblastoma (GBM) cases, which received endorsement from the FDA. This particular device harnesses the power of Tumor Treating Fields (TTFields), a form of oscillating electric fields designed to impede the proliferation of cancerous cells and possibly prolong the lives of patients. With a modest weight of just 2.7 pounds, the Optune Gio has been engineered with patient comfort in mind, enabling its use throughout routine daily routines.
Glioblastoma Multiforme (GBM) Treatment Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the glioblastoma multiforme (gbm) treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc
Access The Complete Glioblastoma Multiforme (GBM) Treatment Market Report:
Glioblastoma Multiforme (GBM) Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the glioblastoma multiforme (GBM) treatment market share in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
